Olmesartán Aurovitas (Olmesartan Medoxomil)

Olmesartan Medoxomil is an antihypertensive agent that works within the renin‑angiotensin‑aldosterone system to lower blood pressure.

• Hypertension: helps achieve target blood pressure and reduces cardiovascular risk.
• Diastolic heart failure: assists in decreasing afterload and improving symptoms.
• Chronic kidney disease with proteinuria: slows progression by lowering intraglomerular pressure.

• Olmesartan Medoxomil selectively blocks the binding of angiotensin II to the AT1 receptor on vascular smooth‑muscle and adrenal cells. This inhibition prevents vasoconstriction and aldosterone secretion, leading to reduced peripheral resistance, lower blood volume, and ultimately a decrease in systemic blood pressure.

Adverse reactions to olmesartan are generally mild to moderate and vary among individuals.

Common Side Effects

• Dizziness: especially after the first dose or when standing quickly.
• Headache: mild to moderate intensity.
• Fatigue: feeling of tiredness without exertion.
• Nasal congestion: mild blockage of the nasal passages.
• Diarrhea: loose, watery stools.
• Cough: non‑productive cough.

Serious or Rare Side Effects

• Angioedema: swelling of the face, lips, tongue or throat that may compromise breathing.
• Hyperkalemia: elevated potassium levels that can affect heart rhythm.
• Acute kidney injury: sudden decline in renal function.
• Severe hypotension: markedly low blood pressure causing faintness or shock.
• Liver enzyme elevation: increased ALT/AST indicating hepatic stress.
• Allergic rash: widespread skin eruption with itching or hives.

When using olmesartan, clinicians should assess patient history and monitor relevant parameters.

• Blood pressure monitoring: check regularly to avoid excessive hypotension.
• Renal function: evaluate serum creatinine and eGFR before initiation and during therapy.
• Electrolyte balance: monitor potassium levels, especially if combined with potassium‑sparing agents.
• Pregnancy: contraindicated in the second and third trimesters due to fetal toxicity.
• Drug interactions: review concomitant medications for potential additive hypotensive effects.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Olmesartan may interact with several medicines, requiring attention to dosage and monitoring.

Major Interactions (Avoid)

• Aliskiren: combined use in diabetic patients can increase risk of renal impairment and hyperkalemia.
• Potassium‑sparing diuretics: may cause dangerous elevations in serum potassium.
• Lithium: concurrent use can raise lithium concentrations and risk toxicity.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function.
• ACE inhibitors: additive blood‑pressure lowering effect; monitor for hypotension.
• Thiazide diuretics: can enhance antihypertensive response and increase risk of electrolyte disturbances.